Wakefield TW - Search Results

1

Mouse complete stasis model of inferior vena cava thrombosis.

Wrobleski SK, Farris DM, Diaz JA, Myers DD Jr, Wakefield TW. Wrobleski SK, et al. Among authors: wakefield tw. J Vis Exp. 2011 Jun 15;(52):2738. doi: 10.3791/2738. J Vis Exp. 2011. PMID: 21712794 Free PMC article.

2

Heparin-mediated reductions of the toxic effects of protamine sulfate on rabbit myocardium.

Wakefield TW, Wrobleski SK, Nichol BJ, Kadell AM, Stanley JC. Wakefield TW, et al. J Vasc Surg. 1992 Jul;16(1):47-53. J Vasc Surg. 1992. PMID: 1619724

3

Reversal of depressed oxygen consumption accompanying in vivo protamine sulphate-heparin interactions by the prostacyclin analogue, iloprost.

Wakefield TW, Wrobleski SK, Stanley JC. Wakefield TW, et al. Eur J Vasc Surg. 1990 Feb;4(1):25-31. doi: 10.1016/s0950-821x(05)80035-0. Eur J Vasc Surg. 1990. PMID: 1691112

4

Deep venous thrombosis in the baboon: an experimental model.

Wakefield TW, Wrobleski SK, Sarpa MS, Taylor FB Jr, Esmon CT, Cheng A, Greenfield LJ. Wakefield TW, et al. J Vasc Surg. 1991 Nov;14(5):588-98. doi: 10.1067/mva.1991.32030. J Vasc Surg. 1991. PMID: 1942366

5

Increased prostacyclin and adverse hemodynamic responses to protamine sulfate in an experimental canine model.

Wakefield TW, Wrobleski SK, Wirthlin DJ, Wang TW, Stanley JC. Wakefield TW, et al. J Surg Res. 1991 May;50(5):449-56. doi: 10.1016/0022-4804(91)90023-f. J Surg Res. 1991. PMID: 2038184 Free article.

6

Impaired myocardial function and oxygen utilization due to protamine sulfate in an isolated rabbit heart preparation.

Wakefield TW, Bies LE, Wrobleski SK, Bolling SF, Stanley JC, Kirsh MM. Wakefield TW, et al. Ann Surg. 1990 Oct;212(4):387-93; discussion 394. doi: 10.1097/00000658-199010000-00001. Ann Surg. 1990. PMID: 2222010 Free PMC article.

7

Venous thrombosis-associated inflammation and attenuation with neutralizing antibodies to cytokines and adhesion molecules.

Wakefield TW, Strieter RM, Wilke CA, Kadell AM, Wrobleski SK, Burdick MD, Schmidt R, Kunkel SL, Greenfield LJ. Wakefield TW, et al. Arterioscler Thromb Vasc Biol. 1995 Feb;15(2):258-68. doi: 10.1161/01.atv.15.2.258. Arterioscler Thromb Vasc Biol. 1995. PMID: 7749835

8

Effective and less toxic reversal of low-molecular weight heparin anticoagulation by a designer variant of protamine.

Wakefield TW, Andrews PC, Wrobleski SK, Kadell AM, Schmidt R, Tejwani S, Stanley JC. Wakefield TW, et al. J Vasc Surg. 1995 May;21(5):839-49; discussion 849-50. doi: 10.1016/s0741-5214(05)80016-3. J Vasc Surg. 1995. PMID: 7769743 Free article.

9

Reversal of low-molecular-weight heparin anticoagulation by synthetic protamine analogues.

Wakefield TW, Andrews PC, Wrobleski SK, Kadell AM, Fazzalari A, Nichol BJ, Vanderkooi T, Stanley JC. Wakefield TW, et al. J Surg Res. 1994 Jun;56(6):586-93. doi: 10.1006/jsre.1994.1093. J Surg Res. 1994. PMID: 8015315 Free article.

10

Tissue distribution, circulating half-life, and excretion of intravenously administered protamine sulfate.

DeLucia A 3rd, Wakefield TW, Kadell AM, Wrobleski SK, VanDort M, Stanley JC. DeLucia A 3rd, et al. Among authors: wakefield tw. ASAIO J. 1993 Jul-Sep;39(3):M715-8. ASAIO J. 1993. PMID: 8268631

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

351 results

Search Page

Filters